Hisun Braces For Hit From US FDA Import Alert
This article was originally published in PharmAsia News
Zhejiang Hisun Pharmaceutical has already seen its net profit slump this year, and now has to face a US import alert for APIs made at one of its Chinese plants on top of a voluntarily quarantine by importers in Canada. The company is nevertheless pushing ahead with the reconstruction of its business model, eyeing global partners for future markets.
You may also be interested in...
The breakup of the Hisun-Pfizer JV typifies an unhappy marriage between Chinese and MNC pharma firms in the generics segment in recent years, although the two companies will continue to work as commercial partners under a new framework. Scrip delves into the reasons for the split and also outlines why, China is, nevertheless, expected to see more joint ventures for innovative drugs.
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.